Macimorelin (AEZS-130)-stimulated growth hormone (GH) test: Validation of a novel oral stimulation test for the diagnosis of adult GH deficiency

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 6, 2013, Pages 2422-2429

  Garcia, Jose M ^a   Swerdloff, R ^b   Wang, C ^b   Kyle, M ^c   Kipnes, M ^d   Biller, B M K ^e   Cook, D ^f   Yuen, K C J ^f   Bonert, V ^g   Dobs, A ^h   Molitch, M E ⁱ   Merriam, G R ^j,k  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c RADIANT RESEARCH   (United States)

^d DGD Clinic   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g CEDARS SINAI MEDICAL CENTER   (United States)

^h DEPARTMENT OF PATHOLOGY   (United States)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

^j UNIVERSITY OF WASHINGTON   (United States)

^k UNIVERSITY OF WASHINGTON   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AR GINE; ARGININE; GEREF DIAGNOSTIC; GROWTH HORMONE; MACIMORELIN; SERMORELIN; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIARRHEA; DRUG SAFETY; DYSGEUSIA; ENDOCRINE FUNCTION TEST; FEMALE; GROWTH HORMONE DEFICIENCY; HUMAN; INCREASED APPETITE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; OBESITY; OPEN STUDY; PRIORITY JOURNAL; QT PROLONGATION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SINGLE DRUG DOSE; T WAVE; WEIGHT GAIN;

ADMINISTRATION, ORAL; ADULT; AGED; ARGININE; CROSS-OVER STUDIES; FEMALE; GHRELIN; GROWTH HORMONE-RELEASING HORMONE; HUMAN GROWTH HORMONE; HUMANS; INDOLES; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; ROC CURVE; TRYPTOPHAN;

EID: 84878514235     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1157     Document Type: Article

References (27)

1. Biller BM, Samuels MH, Zagar A, et al. Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab. 2002;87:2067-2079. (Pubitemid 34521490)
2. Yuen KC, Biller BM, Molitch ME, Cook DM. Clinical review: is lack of recombinant growth hormone (GH)-releasing hormone in the United States a setback or time to consider glucagon testing for adult GH deficiency? J Clin Endocrinol Metab. 2009;94:2702-2707.
3. Ho KK. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol. 2007;157:695-700.
4. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML, Endocrine S. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1587-1609.
5. Attanasio AF, Howell S, Bates PC, et al. Body composition, IGF-I and IGFBP-3 concentrations as outcome measures in severely GH-deficient (GHD) patients after childhood GH treatment: a comparison with adult onset GHD patients. J Clin Endocrinol Metab. 2002;87:3368-3372. (Pubitemid 34822873)
6. Hoffman AR, Kuntze JE, Baptista J, et al. Growth hormone (GH) replacement therapy in adult-onset GH deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89:2048-2056. (Pubitemid 38619832)
7. Woodhouse LJ, Asa SL, Thomas SG, Ezzat S. Measures of submaximal aerobic performance evaluate and predict functional response to growth hormone (GH) treatment in GH-deficient adults. J Clin Endocrinol Metab. 1999;84:4570-4577.
8. Smith JC, Evans LM, Wilkinson I, et al. Effects of GH replacement on endothelial function and large-artery stiffness in GH-deficient adults: a randomized, double-blind, placebo-controlled study. Clin Endocrinol (Oxf). 2002;56:493-501. (Pubitemid 34429624)
9. Bollerslev J, Ueland T, Jorgensen AP, et al. Positive effects of a physiological dose of GH on markers of atherogenesis: a placebo-controlled study in patients with adult-onset GH deficiency. Eur J Endocrinol. 2006;154:537-543.
10. Biller BM, Sesmilo G, Baum HB, Hayden D, Schoenfeld D, Klibanski A. Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset GH deficiency. J Clin Endocrinol Metab. 2000;85:970-976. (Pubitemid 32269335)
11. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656-660. (Pubitemid 129516334)
12. Smith RG, Van der Ploeg LH, Howard AD, et al. Peptidomimetic regulation of growth hormone secretion. Endocr Rev. 1997;18:621-645. (Pubitemid 27435537)
13. Sun Y, Wang P, Zheng H, Smith RG. Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. PNAS. 2004;101:4679-4684. (Pubitemid 38437470)
14. Svensson J, Lonn L, Jansson JO, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab. 1998;83:362-369. (Pubitemid 28496507)
15. Garcia JM, Polvino WJ. Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers. Oncologist. 2007;12:594-600. (Pubitemid 350012123)
16. Broglio F, Boutignon F, Benso A, et al. EP1572: a novel peptidomimetic GH secretagogue with potent and selective GH-releasing activity in man. J Endocrinol Invest. 2002;25:RC26-RC28.
17. Piccoli F, Degen L, MacLean C, et al. Pharmacokinetics and pharmacodynamic effects of an oral ghrelin agonist in healthy subjects. J Clin Endocrinol Metab. 2007;92:1814-1820. (Pubitemid 46997194)
18. Cook DM, Yuen KC, Biller BM, Kemp SF, Vance ML, American Association of Clinical Endocrinology. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients-2009 update. Endocr Pract. 2009;15(suppl 2):1-29.
19. Marcum ZA, Vande Griend JP, Linnebur SA. FDA drug safety communications: a narrative review and clinical considerations for older adults. Am J Geriatr Pharmacother. 2012;10:264-271.
20. Bhatti SF, De Vliegher SP, Mol JA, Van Ham LM, Kooistra HS. Ghrelin-stimulation test in the diagnosis of canine pituitary dwarfism. Res Vet Sci. 2006;81:24-30. (Pubitemid 43323772)
21. Gasco V, Beccuti G, Baldini C, et al. Acylated ghrelin as a provocative test for the diagnosis of GH deficiency in adults. Eur J Endocrinol. 2013;168:23-30.
22. Popovic V, Leal A, Micic D, et al. GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults. Lancet. 2000;356:1137-1142.
23. Pombo M, Leal-Cerro A, Barreiro J, et al. Growth hormone releasing hexapeptide-6 (GHRP-6) test in the diagnosis of GH-deficiency. J Pediatr Endocrinol Metab 1996;9(suppl 3):333-338. (Pubitemid 26258946)
24. Fisker S, Jorgensen JO, Christiansen JS. Variability in growth hormone stimulation tests. Growth Horm IGF Res. 1998;8 (suppl A):31-35.
25. Iranmanesh A, Lizarralde G, Veldhuis JD. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J Clin Endocrinol Metab. 1991;73:1081-1088. (Pubitemid 21901150)
26. Corneli G, DiSomma C, Baldelli R, et al. The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. Eur J Endocrinol. 2005;153:257-264. (Pubitemid 41174451)
27. Ghigo E, Aimaretti G, Gianotti L, Bellone J, Arvat E, Camanni F. New approach to the diagnosis of growth hormone deficiency in adults. Eur J Endocrinol. 1996;134:352-356. (Pubitemid 26108154)